Volitionrx LTD (VNRX) — SEC Filings

Overview

Volitionrx LTD (VNRX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 23, 2026: VolitionRx Ltd. filed an 8-K on April 23, 2026, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The filing also includes other events and financial statements/exhibits.

Sentiment Summary

Across 35 filings, the sentiment breakdown is: 2 bearish, 31 neutral, 2 mixed. The dominant filing sentiment for Volitionrx LTD is neutral.

Filing Type Overview

Volitionrx LTD (VNRX) has filed 20 8-K, 6 10-Q, 1 8-K/A, 1 10-Q/A, 1 DEF 14A, 2 10-K, 2 SC 13G, 1 SC 13G/A, 1 SC 13D/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (35)

• VolitionRx Ltd. Faces Delisting Concerns — 8-K · Apr 23, 2026 Risk: high
  VolitionRx Ltd. filed an 8-K on April 23, 2026, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The filing also incl
• VolitionRx Relocates HQ, Adjusts Fiscal Year End — 8-K · Dec 11, 2025 Risk: low
  VolitionRx Limited announced on December 5, 2025, a change in its principal executive offices to 1489 West Warm Springs Road, Suite 110, Henderson, Nevada 89014
• VolitionRx Narrows Losses Amid Revenue Growth, Cash Dries Up — 10-Q · Nov 13, 2025 Risk: high
  VolitionRx Limited reported a net loss of $17,200,488 for the nine months ended September 30, 2025, a 19.6% improvement from the $21,400,758 net loss in the pri
• VolitionRx Files 8-K/A Amendment — 8-K/A · Nov 10, 2025 Risk: low
  VolitionRx Limited filed an 8-K/A on November 10, 2025, to amend a previous filing. The amendment pertains to the entry into a material definitive agreement and
• 8-K Filing — 8-K · Nov 7, 2025
• VolitionRx Ltd Enters Material Agreement, Reports Financials — 8-K · Oct 14, 2025 Risk: medium
  VolitionRx Limited (VNRX) announced on October 10, 2025, that it has entered into a material definitive agreement. The company also reported its results of oper
• VolitionRx Files 10-Q/A Amendment for Exhibit Inclusion — 10-Q/A · Aug 15, 2025 Risk: low
  VolitionRx Limited filed an Amendment No. 1 on Form 10-Q/A on August 15, 2025, to its quarterly report for the period ended June 30, 2025. This amendment was fi
• VolitionRx Narrows Losses Amid Revenue Growth, R&D Cuts — 10-Q · Aug 14, 2025 Risk: high
  VolitionRx Limited (VNRX) reported a net loss of $11,790,697 for the six months ended June 30, 2025, a significant improvement from the $15,532,180 net loss in
• VolitionRx Limited Files Current Report (8-K) — 8-K · Aug 4, 2025 Risk: low
  On August 1, 2025, VolitionRx Limited entered into a material definitive agreement. The company, previously known as Standard Capital Corp until August 12, 1999
• VolitionRx Files 8-K: Bylaws, Shareholder Votes, Financials — 8-K · Jun 20, 2025 Risk: low
  VolitionRx Limited filed an 8-K on June 20, 2025, reporting events as of June 18, 2025. The filing indicates amendments to articles of incorporation or bylaws,
• VolitionRx Ltd. Q1 2025 10-Q: Assets $175M, Equity $96.1M — 10-Q · May 15, 2025 Risk: medium
  VolitionRx Ltd. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $175 million and total liabilities of $100.7 million,
• VolitionRx Ltd Files Definitive Proxy Statement — DEF 14A · Apr 29, 2025 Risk: low
  VolitionRx Ltd filed its definitive proxy statement on April 29, 2025, for its annual meeting. The filing details the company's governance and executive compens
• VolitionRx Ltd. Enters and Terminates Material Agreements — 8-K · Apr 22, 2025 Risk: medium
  On April 22, 2025, VolitionRx Limited entered into a material definitive agreement and also terminated a material definitive agreement. The company, incorporate
• VolitionRx Files 8-K for Regulation FD Disclosure — 8-K · Apr 4, 2025 Risk: low
  VolitionRx Limited filed an 8-K on April 4, 2025, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or material event
• VolitionRx Ltd. Files 2024 Annual Report — 10-K · Mar 31, 2025 Risk: medium
  VolitionRx Ltd. filed its 10-K for the fiscal year ending December 31, 2024, reporting on its business operations and financial condition. The company, formerly
• VolitionRx Limited Files 8-K: Material Agreement & Other Events — 8-K · Mar 26, 2025 Risk: medium
  On March 24, 2025, VolitionRx Limited entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company als
• VolitionRx Limited Files 8-K with Material Agreement — 8-K · Dec 9, 2024 Risk: medium
  On December 5, 2024, VolitionRx Limited entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company a
• SC 13G Filing — SC 13G · Nov 14, 2024
• VolitionRx Ltd. Q3 2024 10-Q Filed — 10-Q · Nov 14, 2024 Risk: medium
  VolitionRx Ltd. filed its Q3 2024 10-Q report on November 14, 2024, covering the period ending September 30, 2024. The company reported total assets of $175 mil
• SC 13G Filing — SC 13G · Nov 14, 2024
• VolitionRx Appoints New CMO, Elects Director — 8-K · Nov 6, 2024 Risk: medium
  VolitionRx Limited announced on November 6, 2024, the appointment of Dr. Michael J. O'Sullivan as Chief Medical Officer and the election of Ms. Sarah E. Johnson
• VolitionRx Ltd Files 8-K on Officer/Director Changes — 8-K · Sep 30, 2024 Risk: low
  VolitionRx Limited filed an 8-K on September 30, 2024, reporting on the departure of directors or certain officers, the election of directors, the appointment o
• VolitionRx Ltd. Announces Board and Compensation Changes — 8-K · Sep 27, 2024 Risk: medium
  VolitionRx Limited announced on September 26, 2024, a change in its board of directors and executive compensation arrangements. Specifically, the company electe
• VolitionRx to Acquire BioCheck for $10M — 8-K · Sep 16, 2024 Risk: medium
  VolitionRx Limited announced on September 16, 2024, that it has entered into a definitive agreement to acquire all of the outstanding equity interests of BioChe
• VolitionRx Ltd. Files Q2 2024 10-Q, Details Financials — 10-Q · Aug 14, 2024 Risk: medium
  VolitionRx Ltd. filed its 10-Q for the period ending June 30, 2024, reporting a net loss. The company's financial statements indicate a decrease in cash and cas
• VolitionRx Limited Files 8-K — 8-K · Aug 12, 2024 Risk: medium
  On August 8, 2024, VolitionRx Limited entered into a material definitive agreement, the details of which are not fully disclosed in this filing but are indicate
• VolitionRx Ltd. Announces Board and Officer Changes — 8-K · Jul 3, 2024 Risk: medium
  VolitionRx Limited announced on July 2, 2024, a significant change in its corporate structure and leadership. The company filed an 8-K detailing the election of
• VolitionRx Limited Files 8-K Report — 8-K · Jun 27, 2024 Risk: low
  On June 27, 2024, VolitionRx Limited filed an 8-K report. The filing primarily concerns financial statements and exhibits, as well as a Regulation FD Disclosure
• VolitionRx Ltd. Files 10-Q for Q1 2024 — 10-Q · May 13, 2024 Risk: low
  VOLITIONRX LTD (VNRX) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. VolitionRx Ltd. reported financial results for the first quarter ended March
• VolitionRx Appoints New CSO, Board Member — 8-K · Apr 26, 2024 Risk: medium
  VolitionRx Limited announced on April 24, 2024, a change in its board of directors, with the appointment of Dr. David E. Bearss as Chief Scientific Officer and
• VolitionRx Ltd. Files 2023 Annual Report on Form 10-K — 10-K · Mar 25, 2024 Risk: medium
  VOLITIONRX LTD (VNRX) filed a Annual Report (10-K) with the SEC on March 25, 2024. VolitionRx Ltd. reported total assets of $81,898,321 for the fiscal year endi
• VolitionRx to Acquire Private Diagnostics Company — 8-K · Mar 19, 2024 Risk: medium
  VolitionRx Limited announced on March 19, 2024, that it has entered into a definitive agreement to acquire all of the outstanding equity interests of a privatel
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• VolitionRx CEO Reynolds Amends 13D/A, Updates Ownership Stake — SC 13D/A · Feb 9, 2024 Risk: low
  Cameron Reynolds, CEO of VolitionRx Limited, filed an amended Schedule 13D/A on February 9, 2024, updating his beneficial ownership of the company's common stoc
• VolitionRx 8-K: Administrative Update, NYSE American Listing Confirmed — 8-K · Jan 2, 2024
  VolitionRx Limited filed an 8-K on January 2, 2024, reporting an "Other Events" item from December 29, 2023. This filing primarily updates administrative inform

Risk Profile

Risk Assessment: Of VNRX's 30 recent filings, 3 were flagged as high-risk, 16 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Volitionrx LTD's most recent 10-Q filing (Nov 13, 2025):

• Revenue: $1.28M
• Net Income: -$17.2M
• EPS: $0.05
• Debt-to-Equity: N/A
• Cash Position: $199K
• Operating Margin: N/A
• Total Assets: $6.45M
• Total Debt: $42.4M

Key Executives

• Dr. Michael J. O'Sullivan
• Ms. Sarah E. Johnson
• Dr. David E. Bearss
• Cameron Reynolds
• Marc G. Alcser, Esq.

Industry Context

VolitionRx operates in the highly competitive and rapidly evolving cancer diagnostics market. The industry is characterized by significant investment in research and development, stringent regulatory hurdles, and a growing demand for early detection and personalized medicine. Key trends include the advancement of liquid biopsy technologies and the integration of artificial intelligence in diagnostic interpretation.

Top Tags

financials (8) · material-agreement (7) · corporate-governance (7) · filing (4) · 10-Q (4) · diagnostics (4) · Diagnostics (3) · Biotechnology (2) · Going Concern (2) · R&D Spending (2)

Key Numbers

• Net Loss: $17.2M — Decreased by 19.6% from $21.4M in the prior year period.
• Total Revenues: $1.28M — Increased by 22.9% from $1.04M in the prior year period.
• Cash and Cash Equivalents: $199K — Decreased by 93.9% from $3.26M at December 31, 2024.
• Net Cash Used in Operating Activities: $14.19M — Significant cash burn for the nine months ended September 30, 2025.
• Research and Development Expenses: $7.61M — Decreased by 35.5% from $11.82M in the prior year period.
• General and Administrative Expenses: $7.67M — Increased by 20.7% from $6.35M in the prior year period.
• Total Liabilities: $42.4M — Increased from $35.5M at December 31, 2024.
• Total Stockholders' Deficit: $(35.9M) — Deepened from $(26.1M) at December 31, 2024.
• Shares Outstanding: 122,801,572 — As of November 7, 2025.
• Net Loss Per Share (Q3 2025): $0.05 — Improved from $0.07 in Q3 2024.
• Net Proceeds from Convertible Note and Warrants: $5.80M — New financing activity for the six months ended June 30, 2025.
• Net Proceeds from Common Stock Issuances: $2.45M — Capital raised for the six months ended June 30, 2025.
• Net Loss Per Share (Q2 2025): $0.06 — Improved from $0.08 in Q2 2024.
• SEC File Number: 001-36833 — Identifies the company's filing with the SEC
• IRS Employer Identification No.: 91-1949078 — Company's tax identification number

Forward-Looking Statements

• {"claim":"Cameron Reynolds will continue to hold a significant stake in VolitionRx Limited.","entity":"Cameron Reynolds","targetDate":"2025-02-09","confidence":"high"}
• {"claim":"The market will interpret this filing as a routine update rather than a major shift in insider sentiment.","entity":"VolitionRx Limited","targetDate":"2024-02-16","confidence":"medium"}

Frequently Asked Questions